Cullinan Oncology Inc (CGEM)

$16.67

-0.7

(-4.03%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Cullinan Oncology Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 251.9% return, outperforming this stock by 300.3%

Performance

  • $16.53
    $17.39
    $16.67
    downward going graph

    0.84%

    Downside

    Day's Volatility :4.92%

    Upside

    4.11%

    downward going graph
  • $7.64
    $19.68
    $16.67
    downward going graph

    54.17%

    Downside

    52 Weeks Volatility :61.18%

    Upside

    15.29%

    downward going graph

Returns

PeriodCullinan Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
59.06%
-1.1%
0.0%
6 Months
89.43%
6.7%
0.0%
1 Year
63.43%
2.4%
-1.5%
3 Years
-48.36%
17.2%
-20.6%

Highlights

Market Capitalization
748.0M
Book Value
$10.58
Earnings Per Share (EPS)
-3.69
Wall Street Target Price
25.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-22.8%
Return On Equity TTM
-31.37%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
18.9M
EBITDA
-190.3M
Diluted Eps TTM
-3.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.74
EPS Estimate Next Year
-3.34
EPS Estimate Current Quarter
-0.96
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Cullinan Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.97%

Current $16.67
Target $25.50

Technicals Summary

Sell

Neutral

Buy

Cullinan Oncology Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cullinan Oncology Inc
Cullinan Oncology Inc
-1.83%
89.43%
63.43%
-48.36%
72694.76%
Moderna, Inc.
Moderna, Inc.
-1.29%
6.96%
-34.5%
-29.77%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.29%
7.75%
8.95%
89.65%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-6.73%
21.9%
48.54%
251.87%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.03%
6.89%
18.96%
83.64%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cullinan Oncology Inc
Cullinan Oncology Inc
9.03
NA
NA
-3.74
-0.31
-0.23
NA
10.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cullinan Oncology Inc
Cullinan Oncology Inc
Buy
$748.0M
72694.76%
9.03
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • MPM Oncology Impact Management LP

    17.76%
  • Blue Owl Capital Holdings LP

    7.94%
  • CHI Advisors LLC

    7.93%
  • Franklin Resources Inc

    7.62%
  • Bvf Inc

    7.42%
  • BlackRock Inc

    5.72%

Company Information

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

Organization
Cullinan Oncology Inc
Employees
85
CEO
Mr. Nadim Ahmed
Industry
Other Consumer Services

FAQs